ChromaDex (CDXC) News Today $3.07 -0.12 (-3.76%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 26 at 11:59 AM | marketbeat.comShort Interest in ChromaDex Co. (NASDAQ:CDXC) Increases By 68.4%ChromaDex Co. (NASDAQ:CDXC - Get Free Report) was the recipient of a large increase in short interest in the month of July. As of July 15th, there was short interest totalling 3,150,000 shares, an increase of 68.4% from the June 30th total of 1,870,000 shares. Currently, 6.5% of the shares of the company are short sold. Based on an average daily volume of 385,100 shares, the days-to-cover ratio is currently 8.2 days.July 23, 2024 | finance.yahoo.comChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)July 22, 2024 | businesswire.comChromaDex Appoints Carlos Lopez as Senior Vice President, General CounselJuly 10, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) Share Price Passes Above Two Hundred Day Moving Average of $2.55ChromaDex (NASDAQ:CDXC) Share Price Crosses Above 200-Day Moving Average of $2.55July 1, 2024 | marketbeat.comChromaDex Co. (NASDAQ:CDXC) Short Interest Up 10.7% in JuneChromaDex Co. (NASDAQ:CDXC - Get Free Report) was the target of a large increase in short interest in June. As of June 15th, there was short interest totalling 1,870,000 shares, an increase of 10.7% from the May 31st total of 1,690,000 shares. Based on an average trading volume of 323,100 shares, the days-to-cover ratio is currently 5.8 days. Currently, 3.9% of the company's stock are short sold.June 28, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) Share Price Passes Above 200-Day Moving Average of $2.47ChromaDex (NASDAQ:CDXC) Stock Crosses Above 200 Day Moving Average of $2.47June 24, 2024 | businesswire.comMilestone Phase II Clinical Study Demonstrates Niagen®, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD)June 13, 2024 | businesswire.comChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)June 12, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) Given "Buy" Rating at Roth MkmRoth Mkm reaffirmed a "buy" rating and set a $6.00 price target on shares of ChromaDex in a research report on Wednesday.June 7, 2024 | businesswire.comChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)June 6, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) Shares Cross Above Two Hundred Day Moving Average of $2.32ChromaDex (NASDAQ:CDXC) Shares Cross Above Two Hundred Day Moving Average of $2.32June 4, 2024 | businesswire.comChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, June 11, 2024May 27, 2024 | msn.comCompare with Chromadex Corp (CDXC)May 23, 2024 | businesswire.comChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024May 22, 2024 | finance.yahoo.comChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year AwardMay 22, 2024 | businesswire.comChromaDex's Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year AwardMay 21, 2024 | marketbeat.comTieton Capital Management LLC Increases Stake in ChromaDex Co. (NASDAQ:CDXC)Tieton Capital Management LLC raised its position in shares of ChromaDex Co. (NASDAQ:CDXC - Free Report) by 18.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,913,675 shares of the company's stock after buying an addiMay 10, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue EstimatesMay 10, 2024 | marketbeat.comChromaDex Co. (NASDAQ:CDXC) Expected to Earn Q1 2025 Earnings of $0.00 Per ShareChromaDex Co. (NASDAQ:CDXC - Free Report) - Analysts at Roth Capital decreased their Q1 2025 earnings estimates for shares of ChromaDex in a report issued on Thursday, May 9th. Roth Capital analyst S. Mcgowan now expects that the company will post earnings per share of $0.00 for the quarter, downMay 9, 2024 | markets.businessinsider.comChromadex Poised for Continued Growth; Selvaraju Reiterates Buy Rating with $6 TargetMay 9, 2024 | finance.yahoo.comChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ...May 9, 2024 | marketbeat.comChromaDex's (CDXC) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $6.00 target price on shares of ChromaDex in a research report on Thursday.May 8, 2024 | investorplace.comCDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | msn.comChromaDex GAAP EPS of -$0.01 in-line, revenue of $22.2M misses by $1.41MMay 8, 2024 | finance.yahoo.comChromaDex Corporation Reports First Quarter 2024 Financial ResultsMay 7, 2024 | markets.businessinsider.comChromaDex is about to announce its earnings — here's what to expectMay 6, 2024 | finance.yahoo.comAn Intrinsic Calculation For ChromaDex Corporation (NASDAQ:CDXC) Suggests It's 43% UndervaluedMay 1, 2024 | marketbeat.comChromaDex Co. (NASDAQ:CDXC) Short Interest UpdateChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,480,000 shares, an increase of 12.1% from the March 31st total of 1,320,000 shares. Approximately 3.3% of the company's shares are sold short. Based on an average daily volume of 309,600 shares, the short-interest ratio is presently 4.8 days.May 1, 2024 | finance.yahoo.comChromaDex Corporation (CDXC)May 1, 2024 | marketbeat.comChromaDex (CDXC) Set to Announce Quarterly Earnings on WednesdayChromaDex (NASDAQ:CDXC) will be releasing earnings after the market closes on Wednesday, May 8, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588558)April 30, 2024 | finance.yahoo.comChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementApril 30, 2024 | businesswire.comChromaDex's NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementApril 25, 2024 | businesswire.comChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®April 24, 2024 | businesswire.comChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024April 23, 2024 | businesswire.comChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketApril 17, 2024 | msn.comChromaDex (CDXC) Price Target Increased by 9.92% to 6.60April 14, 2024 | marketbeat.comShort Interest in ChromaDex Co. (NASDAQ:CDXC) Grows By 12.8%ChromaDex Co. (NASDAQ:CDXC - Get Free Report) was the target of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 1,320,000 shares, an increase of 12.8% from the March 15th total of 1,170,000 shares. Approximately 3.0% of the shares of the company are short sold. Based on an average daily trading volume, of 259,700 shares, the short-interest ratio is presently 5.1 days.April 9, 2024 | marketbeat.comChromaDex (NASDAQ:CDXC) PT Raised to $6.00Roth Mkm upped their price target on ChromaDex from $4.25 to $6.00 and gave the company a "buy" rating in a report on Tuesday.March 27, 2024 | stocknews.com3 Chemical Stocks Poised for GainsMarch 26, 2024 | businesswire.comChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency ProgramMarch 19, 2024 | marketbeat.comShort Interest in ChromaDex Co. (NASDAQ:CDXC) Declines By 9.0%ChromaDex Co. (NASDAQ:CDXC - Get Free Report) saw a significant decline in short interest in the month of February. As of February 29th, there was short interest totalling 1,210,000 shares, a decline of 9.0% from the February 14th total of 1,330,000 shares. Based on an average daily volume of 81,100 shares, the short-interest ratio is currently 14.9 days. Currently, 2.7% of the shares of the company are sold short.March 14, 2024 | marketbeat.comEquities Analysts Offer Predictions for ChromaDex Co.'s FY2025 Earnings (NASDAQ:CDXC)ChromaDex Co. (NASDAQ:CDXC - Free Report) - Analysts at HC Wainwright issued their FY2025 earnings estimates for ChromaDex in a research note issued to investors on Monday, March 11th. HC Wainwright analyst R. Selvaraju forecasts that the company will earn $0.07 per share for the year. The consenMarch 8, 2024 | finance.yahoo.comChromaDex Full Year 2023 Earnings: EPS Beats ExpectationsMarch 8, 2024 | marketbeat.comChromaDex Co. Forecasted to Earn Q1 2025 Earnings of $0.01 Per Share (NASDAQ:CDXC)ChromaDex Co. (NASDAQ:CDXC - Free Report) - Investment analysts at Roth Capital issued their Q1 2025 EPS estimates for shares of ChromaDex in a report issued on Thursday, March 7th. Roth Capital analyst S. Mcgowan anticipates that the company will earn $0.01 per share for the quarter. The consensMarch 8, 2024 | uk.sports.yahoo.comPersona 3 Reload is getting the DLC it needs, but not the one it deservesMarch 7, 2024 | finance.yahoo.comChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | finance.yahoo.comChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDAMarch 6, 2024 | markets.businessinsider.comWhat Wall Street expects from ChromaDex's earningsMarch 6, 2024 | investorplace.comCDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023 Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address Man who Predicted Trump 2016 Win: “Prepare for Election Meltdown” (Ad)Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… A predicted Trump would win. You won’t believe what he’s predicting now. Click here to see it because it’s a SHOCKER… CDXC Media Mentions By Week CDXC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDXC News Sentiment▼0.460.61▲Average Medical News Sentiment CDXC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDXC Articles This Week▼51▲CDXC Articles Average Week Get ChromaDex News Delivered to You Automatically Sign up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: MDWD News Today NAII News Today MTEX News Today USNA News Today FDMT News Today COGT News Today DNTH News Today NUVB News Today EOLS News Today WVE News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDXC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ChromaDex Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share ChromaDex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.